Sign In
Buy PSNL
$10.78
-0.360 (-3.23%)
At Close: Jun 03, 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highli
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
04:01pm, Wednesday, 28'th Jan 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual
Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of “Moderate Buy” by Analysts
04:39am, Tuesday, 20'th Jan 2026
Shares of Personalis, Inc. (NASDAQ: PSNL - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the company, Market
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
04:00pm, Monday, 12'th Jan 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
08:00am, Thursday, 08'th Jan 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
12:23pm, Monday, 05'th Jan 2026
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages
02:14am, Friday, 26'th Dec 2025
Shares of Personalis, Inc. (NASDAQ: PSNL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. One resear
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of “Moderate Buy” by Brokerages
01:26am, Friday, 26'th Dec 2025
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports.
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
06:00am, Wednesday, 17'th Dec 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a j
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
09:00am, Thursday, 11'th Dec 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive pa
Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 68,679 Personalis, Inc. $PSNL
03:58am, Friday, 21'st Nov 2025
Connor Clark and Lunn Investment Management Ltd. acquired a new position in Personalis, Inc. (NASDAQ: PSNL) in the second quarter, according to its most recent 13F filing with the Securities and Excha
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
04:01pm, Tuesday, 18'th Nov 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
09:00am, Monday, 10'th Nov 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test fo
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
09:46pm, Tuesday, 04'th Nov 2025
Personalis, Inc. ( PSNL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Christopher Hall - President, CEO & Director Aaron Tachibana - CFO & COO Richard Chen - Executive VP o
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
06:31pm, Tuesday, 04'th Nov 2025
Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.64 per share a year ago.
